English
Home > Products > CAS NO 2991-28-8

China CAS NO 2991-28-8 Factory

No matter new customer or old customer, We believe in long term and trusted relationship for CAS NO 2991-28-8,2991-28-8,2,5-Difluorobenzoic acid, Prospects first! Whatever you require, we should do our utmost to help you. We warmly welcome clients from all around the globe to cooperate with us for mutual enhancement.
CAS NO 2991-28-8, High output volume, top quality, timely delivery and your satisfaction are guaranteed. We welcome all inquiries and comments. If you are interested in any of our items or have an OEM order to fulfill, make sure you feel free to contact us now. Working with us will save you money and time.

Related Products

Hot Products

  • Gemcitabine hydrochloride

    Gemcitabine hydrochloride

    Product Name:Gemcitabine hydrochloride
    Molecular Formula:C9H12ClF2N3O4
    Molecular Weight;299.66
    CAS Registry Number;122111-03-9
  • 1-Methyl-aminomethyl naphthalene

    1-Methyl-aminomethyl naphthalene

    Product Name:1-Methyl-aminomethyl naphthalene
    Molecular Formula:C12H13N
    Molecular Weight:171.24
    CAS Registry Number:14489-75-9
  • Sodium Nitroprusside Dihydrate

    Sodium Nitroprusside Dihydrate

    Product Name:Sodium Nitroprusside Dihydrate
    Molecular Weight:297.95
    CAS Registry Number:13755-38-9
  • L-Histidine

    L-Histidine

    Product Name:L-Histidine
    Molecular Formula:C6H9N3O2
    Molecular Weight:155.15
    CAS Registry Number:71-00-1
  • 9-Anthracenemethanol

    9-Anthracenemethanol

    Product Name:9-Anthracenemethanol
    Molecular Formula:C15H12O
    Molecular Weight:208.26
    CAS Registry Number:1468-95-7
  • N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE

    N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE

    Product Name:N'-(2-CYANO-4-NITROPHENYL)-N,N-DIMETHYLIMINOFORMAMIDE
    Molecular Formula:C10H10N4O2
    Molecular Weight:218.21
    CAS Registry Number:39263-34-8
  • Related Blog
  • Reviews

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept